Table 4 Function of proteins biomarkers in relation to ovarian cancer and platelets
From: Platelet protein biomarker panel for ovarian cancer diagnosis
Protein name | Associated pathologic conditions | |
|---|---|---|
ovarian cancer | platelet disorders | |
ACTN1 | not studied | |
ACTN4 | ↑ in ovarian cancer [39] | |
CD41/CD61 | platelets contribute to ovarian cancer growth [35] | deficient in Glanzmann thrombasthenia type II [41] |
CRKL | ↑ in ovarian cancer [42] | ST - elevated myocadial infarction [43] |
ERP29 | not studied | mediator of thrombus formation [44] |
GELS | ↑ in serum in ovarian cancer [45] | ↑ in megakaryoblastic leukemia [46], ↑ in thrombin-activated platelets [47] |
HSPA8 | ↑ in ovarian cancer, a potential therapy target [48] | mediator of thromboembolism [49] |
MPST | not studied | not clarified |
PHB | ↑ in paclitaxel-resistant ovarian cancer [30] ↓ in platinum-resistant ovarian cancer [32] | mediator of platelet aggregation [50] |
SRC | therapy-target for thyrosine-kinase inhibitor in ovarian cancer [51], resistance to cis-platin [33] | ST - elevated myocadial infarction [43] |
SERPINB6 | not studied | inhibitor of thrombin [25] |
TLN1 | myelodysplastic syndrome [40] | |
TUBB1, TUBA4 | ↑ in ovarian cancer, mediator of paclitaxel resistance [31] | ↑ in thrombin-activated platelets [47], gene mutation in autosomal dominant macrothrombocytopenia [25] |
WDR1 | mediator of TLN1-induced activation of CD41/CD61 [54] | |